ALLO-GLUE
LIVE

Serial Number

97716240

Owner

Orionis Biosciences Inc.

Attorney

Rachelle A. Dubow, Esq.

Filing Date

Dec 13, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ALLO-GLUE Trademark

Serial Number: 97716240

ALLO-GLUE is a trademark filed by Orionis Biosciences Inc. on December 13, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Orionis Biosciences Inc. (8 trademarks)

Waltham, MA 02451

Entity Type: 03

Trademark Details

Filing Date

December 13, 2022

Registration Date

Not Registered

Published for Opposition

October 31, 2023

Goods & Services

Pharmaceutical products, serums and preparations for the treatment of cancer, auto immune disorders, metabolic disorders, neurological disorders, neuromuscular disorders; Biochemical preparations for medical purposes for use in the treatment of cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases

Diagnostic and chemical reagents for scientific and research use; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; Active chemical ingredients for use in the manufacture of small molecule pharmaceuticals for treating cancer, auto immune diseases, metabolic diseases, neurological diseases, neuromuscular diseases

Development of new technology for others in the field of biotechnology; scientific research and laboratory research services in the medical, bacteriological and biotechnical fields; biotechnical research; technical consultation and research in the field of biotechnological research; Consulting services in the fields of biotechnology and pharmaceutical research and development; consulting services in the field of laboratory testing for scientific purposes in the field of pharmaceuticals and biotechnology; consulting services in the field of research and development of new products relating to diagnosis of diseases; consulting services in the field of pharmacogenetics; research and development of pharmaceuticals for others; scientific and medical research in the fields of oncology, immunology and immune-oncology, inflammation, immune-mediated diseases, protein homeostasis, epigenetics and protein metabolism

Filing History

CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 11, 2026 AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 6, 2026 AITU
TEAS STATEMENT OF USE RECEIVED
Dec 16, 2025 EISU
TEAS REQUEST TO DIVIDE RECEIVED
Dec 16, 2025 ERTD
SOU TEAS EXTENSION RECEIVED
Dec 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 20, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jun 20, 2025 EX3G
SOU EXTENSION 3 FILED
Jun 20, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 20, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 3, 2025 EXRA
SOU EXTENSION 2 GRANTED
Dec 23, 2024 EX2G
SOU EXTENSION 2 FILED
Dec 23, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Dec 23, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 13, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jun 11, 2024 EX1G
SOU EXTENSION 1 FILED
Jun 11, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 11, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 26, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 31, 2023 NPUB
PUBLISHED FOR OPPOSITION
Oct 31, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 11, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 22, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 22, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 22, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 22, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 22, 2023 CNEA
ASSIGNED TO EXAMINER
Sep 16, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 10, 2023 NWOS
NEW APPLICATION ENTERED
Dec 16, 2022 NWAP